Researchers have discovered sequence-specific interactions between hepatitis B proteins and pre-genome RNA that may play a crucial role in nucleocapsid assembly. This could be targeted in future drug development.
Browsing: Basic > Drug Development
Researchers have reported a small-molecule inhibitor of Candida albican protein Bdf1 and demonstrated the compound yields decreased fungal viability, suggesting a possible future antifungal.
As part of the authors ongoing research efforts dedicated to the discovery of novel cruzain inhibitors, a series of benzimidazole derivatives was used to develop predictive 2D and 3D quantitative structure–activity relationship (QSAR) models.
Improved therapeutic strategies are in urgent need for better control and eradication of tuberculosis. In this editorial, the authors evaluate interleukin-37 as a new molecular target for the therapy of tuberculosis.
In this exclusive piece the authors discuss the choice of peptide antigen, delivery system/adjuvant and delivery route as key factors in the development of an effective human vaccine against group A Streptococcus.
Resistance to β-lactams is an increasing problem. This review outlines various approaches taken to discover MBL inhibitors, with an emphasis on the different chemical classes of inhibitors.
Researchers have uncovered metabolic changes in Mycobacterium tuberculosis, which may enable the bacteria to withstand exposure to antimicrobials, suggesting that targeting these pathways could reduce treatment times.
This review aims to provide a better understanding of HEV71 virology and potential antivirals for progressive clinical development with respect to their elucidated mechanistic actions.
Researchers have discovered that investigational cancer drug, BEZ235, may reduce the severity of influenza infection by altering host-cell metabolism, representing new treatment avenues.